Utrecht University

The Department of Internal Medicine at Utrecht University is investigating novel therapeutic approaches, including the impact of medication adjustments and the safety of emerging agents.

• Evaluation of aspirin omission on bleeding and ischemic outcomes
• Safety profiling of the metabolic modulator mitapivat
• Optimization of non‑device based treatment strategies

Six investigators are conducting two active trials, aiming to refine treatment protocols while maintaining patient safety.

Research focuses on improving care for patients with acute coronary events, specifically non‑ST‑segment elevation acute coronary syndrome.

• Bleeding risk management in acute coronary syndrome
• Ischemic event prevention without compromising safety
• Clinical outcomes of revised antiplatelet regimens

The trials aim to demonstrate that modified therapy can be non‑inferior to current standards while reducing complications.

The site is evaluating therapeutic options for erythrocyte membranopathies, targeting improved patient outcomes.

• Assessment of mitapivat safety in red‑cell membrane disorders
• Investigation of metabolic support for hemolytic anemia
• Monitoring of adverse events and quality of life

By studying these rare conditions, investigators hope to expand treatment options for affected individuals.